Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic natural killer cell therapy
- Development stage
- Unknown
- Lead developer
- The Third Affiliated Hospital of Sun Yat-sen University
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an adoptive cellular immunotherapy utilizing allogeneic natural killer (NK) cells derived from the peripheral blood of related donors (siblings) with the same blood type. Developed by the Third Affiliated Hospital of Sun Yat-Sen University, the therapy is being investigated for the treatment of recurrent hepatocellular carcinoma (HCC) in patients who have undergone liver transplantation. The treatment involves culturing donor-derived NK cells and infusing them into patients at two-week intervals. The primary goal of this therapy is to restore anti-tumor immunity in transplant recipients whose immune systems are typically suppressed by post-transplant medication, thereby preventing or treating the recurrence of HCC. Clinical evaluation (NCT02399735) has focused on safety and dosing regimens in combination with conventional treatments.
- Other names
- NK cells from SibshipNK cells-Third Affiliated Hospital, Sun Yat-Sen University-hepatocellular carcinomaadoptive NK cell therapy
Beyond the preview
Go deeper on allogeneic natural killer cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic natural killer cell therapy.